Research suggests GIP activation improves insulin sensitivity in adipose tissue, may contribute to central nervous system appetite regulation beyond what GLP-1 provides, and appears to reduce some of the gastrointestinal side effects associated with GLP-1 agonism alone
This treatment resulted in a significant reduction in mean PASI and DLQI scores, improved skin lesions, and reduced levels of interleukin (IL)17, IL-23, and tumor necrosis factor alpha (TNF)
Forty-four percent of firms with 1,000 to 4,999 workers, and 59% of firms with 5,000 or more workers, say that the use of these medications for weight loss was higher than expected
However, concerns remain about hepatotoxicity, QTc prolongation, torsades de pointes, bradycardia, GI upset, and elevated serum creatinine (40)
Regulatory standards for supplement manufacturing are less stringent than those for pharmaceuticals, which contributes to contamination and mislabeling